CAY10570 |
| Catalog No.GC43172 |
The enzyme fatty acid amide hydrolase (FAAH) is capable of hydrolyzing and inactivating anandamide and other fatty acid amides that act as agonists for the central cannabinoid (CB1) receptor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 875014-22-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
The enzyme fatty acid amide hydrolase (FAAH) is capable of hydrolyzing and inactivating anandamide and other fatty acid amides that act as agonists for the central cannabinoid (CB1) receptor. CAY10570 is a reversible competitive inhibitor of FAAH activity exhibiting an IC50 value of 1.3 µM. CAY10570 has no affinity for the human CB1 receptor and acts as a competitive inhibitor of FAAH activity without being hydrolyzed by the enzyme.
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *